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A precise control of vesicular trafﬁcking is crucial not only for osteoclastic bone resorp-
tion, but also for the crosstalk between osteoclasts and osteoblasts, which regulates bone
homeostasis. In addition to the release of growth factors and modulators, such as gluta-
mate, ﬂux through the intracellular trafﬁcking routes could also provide the osteoclast with
a monitoring function of its resorption activity. To establish the signaling pathways regu-
lating trafﬁcking events in resorbing osteoclasts, we used the bone conserving hormone
calcitonin, which has the unique property of inducing osteoclast quiescence. Calcitonin
acts through the calcitonin receptor and activates multiple signaling pathways. By moni-
toring trafﬁcking of a ﬂuorescent low molecular weight probe in mature, bone resorbing
osteoclasts we show for the ﬁrst time that calcitonin blocks endocytosis from the rufﬂed
border by phospholipase C (PLC) activation. Furthermore, we identify a requirement for
polyunsaturated fatty acids in endocytic trafﬁcking in osteoclasts. Inhibition of PLC prior to
calcitonin treatment restores endocytosis to 75% of untreated rates. This effect is inde-
pendent of protein kinase C activation and can be mimicked by an increase in intracellular
calcium.We thus deﬁne an essential role for intracellular calcium levels in the maintenance
of endocytosis in osteoclasts.
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INTRODUCTION
Bone homeostasis is a dynamic process, which relies on the
crosstalk between bone forming osteoblasts, bone resident osteo-
cytes, and bone resorbing osteoclasts (Matsuo, 2012; Xiong and
O’Brien, 2012). Imbalances in the crosstalk between these cell
types can lead to metabolic bone diseases such as osteoporosis
and osteopetrosis (Teti, 2011). This important process is con-
trolled by locally released factors as well as close cell interactions
(Cao, 2011). During bone resorption, osteoclasts remove large
amounts of extracellular matrix, including growth factors that
are stored in the matrix, excavating deep holes in the bone. Even
though our understanding of the osteoclast life cycle has increased
dramatically over the last decade, the mechanisms that regulate
resorption at the cellular level are only starting to emerge (Mellis
et al., 2011). At the beginning of the resorption cycle, the plasma
membrane in contact with the bone expands through fusion of
lysosomes and intracellular vesicles into the highly convoluted ruf-
ﬂed border. The insertion of vacuolar proton ATPase (VATPase)
and release of lysosomal proteases provide the microenvironment
necessary for resorption of both the organic and inorganic part of
the bone (Vaananen and Laitala-Leinonen, 2008). Recent evidence
suggests that these exocytic events are controlled by Rab7, synap-
totagmin VII, LIS1, and PLEKHM1 (for review see Coxon and
Taylor, 2008). Digested material is removed from the resorption
pit by endocytosis and trafﬁcked through the osteoclast via a tran-
scytotic route to be released at the functional secretory domain at
the bone avert side of the cell (Vaananen and Laitala-Leinonen,
2008). The transcytotic route is important in coupling osteoclast
activity with the mesenchymal cell lineage as growth factors such
as TGFβ (Karsdal et al., 2007), which are liberated from the bone
matrix during resorption, and paracrine signals including gluta-
mate, are released through this route (Morimoto et al., 2006). The
extracellular calcium released during the resorption process is also
trafﬁcked through the osteoclasts (Yamaki et al., 2005) and plays
an important role in mediating osteoclast activity. High extracel-
lular calcium concentrations, as generated in the resorption pit,
inhibit osteoclast differentiation and bone resorption (Malgaroli
et al., 1989; Mentaverri et al., 2006). However, in vitro responses
to high extracellular calcium concentrations differ in osteoclasts
that are plated on glass to those plated on dentine, indicating
that in vivo actively resorbing osteoclasts either employ different
calcium sensing mechanisms to inactive cells or have very efﬁ-
cient mechanisms of removing extracellular calcium (Lakkakorpi
et al., 1996; Stenbeck and Horton, 2000). Capacitive calcium entry
and calcium store reﬁlling are important factors in osteoclast sur-
vival (Lakkakorpi et al., 1996; Mentaverri et al., 2003). In other
cell systems it has been shown that calcium is not only essential
for exocytosis but also for intracellular trafﬁcking and endocyto-
sis (Hay, 2007; Pizzo et al., 2011; Shen et al., 2011). Therefore, it
is likely that intracellular calcium levels play a role in regulating
endocytosis and transcytosis in resorbing osteoclasts.
Most systemic hormones act through osteoblasts to control
osteoclast differentiation and activity. However, calcitonin, a pep-
tide hormone secreted by the parafollicular cells of the thyroid
and a major player in calcium homeostasis, acts directly on the
osteoclast. Calcitonin has rapid inhibitory effects on the activity
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and morphology of osteoclasts, which include inhibition of traf-
ﬁcking to and from the rufﬂed border (Lucht, 1973; Baron et al.,
1990) and profound alterations of the cytoskeleton (Chambers
et al., 1984; Shyu et al., 2007). These effects have a rapid onset and
in vitro changes to the rufﬂed border begin to appear after 15 min
leading to its almost complete disappearance after 60min of treat-
ment (Baron et al., 1990). Enzymes located at the rufﬂed border
before calcitonin treatment are found in cytoplasmic vacuoles.
The effects of calcitonin are mediated by the calcitonin receptor
(CTR), a G protein-coupled receptor linked to Gs, Gi/o, and Gq
trimeric G-proteins. Activation of the different G-proteins leads
to activation of multiple signaling effectors, including adenylyl
cyclase; protein kinase A (PKA); phospholipases C, D, and A2;
and protein kinase C (PKC; Horne et al., 1994; Naro et al., 1998;
Inzerillo et al., 2002). Recently, the discovery that osteoclasts are
having a signiﬁcant role in providing bone forming signals has
led to renewed interest in calcitonin as a treatment for osteoporo-
sis and osteoarthritis (Henriksen et al., 2010). Calcitonin directly
targets osteoclasts in a transient manner, which leads to the ces-
sation of resorption without removing the osteoclasts. However,
signals leading to the cessation of resorption are poorly deﬁned
and it is still unclear what deﬁnes pit depth and length. One
hypothesis is that ﬂow through the different vesicular trafﬁcking
pathways could impart a monitoring function to the osteoclast
of its resorption activity. It is thus important to elucidate the
mechanisms controlling endocytosis and transcytosis in osteo-
clasts. During resorption osteoclasts closely attach to the bone
matrix with podosomes forming a dense actin ring that encloses
the rufﬂed border. This adhesive structure is restricting access to
the resorption area, only allowing access to probes with molecular
weights smaller than 10,000 kDa (Stenbeck and Horton, 2000).
We have previously shown that low molecular weight markers like
TRITC-labeled dextran 3,000 (Stenbeck andHorton, 2004), which
have access to the resorption area, are efﬁciently endocytosed and
access the transcytotic route after endocytosis.
Here we use endocytosis of TRITC-labeled dextran 3,000 as
an efﬁcient way to establish the signaling pathways regulating traf-
ﬁcking events inmature, resorbing osteoclasts after treatment with
the bone conserving hormone calcitonin. To observe uptake of
digested material, endocytosis of TRITC-labeled dextran 3,000 is
well suited as it follows a similar pathway to the resorbed bone
through the osteoclasts and makes labeling of bone and its associ-
ated problems, e.g., surface restriction of the label or the necessity
of whole animal experiments with tetracycline, redundant. Addi-
tionally,with the technique it is possible to analyze immediate early
effects elicited by hormones as well as drugs on resorbing cells,
thus complementing electrophysiological experiments, which are
more difﬁcult to undertake on bone resorbing cells. We show that
calcitonin blocks endocytosis from the rufﬂed border by activat-
ing phospholipase C (PLC). Furthermore, we deﬁne an essential
role for intracellular calcium oscillations in the maintenance of
endocytosis and transcytosis during resorption.
MATERIALS AND METHODS
MATERIALS
Fluorescent dextran (TRITC-dextran, MW of 3,000), Alexa-
Fluor488- and AlexaFluor647-conjugated phalloidin as well as
AlexaFluor488-labeled goat anti-mouse secondary antibodies
were fromMolecular Probes (Leiden, Netherlands). Tissue culture
materials were obtained from Invitrogen (Paisley, UK). Salmon
calcitonin, the PLC inhibitor 1-[6-[[(17β)-3-methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1 H-pyrrole-2,5-dione (U-
73122) and its inactive analog U-73343; protein kinase A
inhibitor N-[2-[[3-(4-bromophenyl)-2-propenyl]amino]ethyl]-
5-isoquinolinesulfonamide dihydrochloride (H-89), cell-perme-
able calcium chelator BAPTA-AM, ionomycin, thapsigargin,
protein kinase C inhibitor bisindolylmaleimide I (BIS) and
chelerythrine chloride, protein kinase C activator phorbol-
12-myristate-13-acetate (PMA), phosphodiesterase inhibitor 3-
isobutyl-1-methylxanthine (IBMX), and 8-bromo-cAMP were
from Calbiochem (Nottingham, UK). cAMP-dependent protein
kinase inhibitor Rp-cAMPS was from Biomol (Enzo Life Sciences,
Exceter, UK). 6-monobutyric cAMP (6-MB-cAMP), diacylglyc-
erol kinase inhibitor 3-[2-[4-[bis(4-Fluorophenyl)methylene]-
1-piperidinyl]ethyl]-2, 3-dihydro-2-thioxo-4(1H)-quinazolinone
(R59949) anddiacylglycerol lipase inhibitorO,O’-[1,6-Hexanediyl
bis(iminocarbonyl)]dioximecyclohexanone (RHC 80267) were
from Sigma (Poole, UK). Stock solutions of the inhibitors were
prepared in DMSO and in every relevant experiment an equiv-
alent volume of DMSO was added to control samples. Anti-
αvβ3 antibodies (clone 23C6) were described previously (Davies
et al., 1989).
ISOLATION AND CULTURE OF OSTEOCLASTS
To assess the modulation of trafﬁcking during bone resorption
we used osteoclasts derived from neonatal rabbits as a readily
available source of mature osteoclasts with morphology simi-
lar to human osteoclasts. The procedure used to culture rabbit
osteoclasts was modiﬁed from the original method developed
by Tezuka et al. (1992) and as described in Stenbeck and Hor-
ton (2004). Brieﬂy, osteoclasts were mechanically disaggregated
from long bones of 5-day old rabbits in α-MEM containing 2 mM
L-glutamine, 100 i.u./ml penicillin, 100 μg/ml streptomycin. The
cells were then pelleted, resuspended in α-MEM containing 2 mM
L-glutamine, 100 i.u./ml penicillin, 100 μg/ml streptomycin, 10%
fetal bovine serum (FBS) and allowed to attach to sonicated den-
tine slices (100–150 μm thick, surface area 0.3 cm2) at 37◦C in 5%
CO2/95% air for 60 min. Non-adherent cells were then washed
away and the remaining cells were cultured for 20 h in α-MEM
containing 2 mM L-glutamine, 100 i.u./ml penicillin, 100 μg/ml
streptomycin, and 10% FBS.
MEASUREMENT OF ENDOCYTOSIS
To measure endocytosis from the rufﬂed border, osteoclasts
on dentine slices were incubated overnight and then treated
with ﬂuorescent-labeled dextran (TRITC-dextran) as described in
Stenbeck and Horton (2004). Brieﬂy, cells on dentine slices were
transferred into α-MEM buffered with 20 mM HEPES (pH 7.0)
containing 2 mM L-glutamine, 100 i.u./ml penicillin, 100 μg/ml
streptomycin, and 0.1%BSA (MEM-BSA) and incubated for 5min
inMEM-BSA containing 260μMof TRITC-labeled dextran 3,000.
Routinely between 48 and 75 % of integrin αvβ3 positive multi-
nucleated cells were endocytosis positive. The incubations were
stopped by washing the cells on dentine slices twice with PBS for
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20 s followed by the immediate addition of 3% paraformalde-
hyde, 2% sucrose in PBS for 10 min at RT. Images shown are
representative of a minimum of 50 different osteoclasts.
For pharmacological experiments, osteoclasts on dentine slices
were pre-incubated for 5–30 min at 37◦C in MEM-BSA con-
taining the appropriate drug before addition of TRITC-labeled
dextran 3,000. Inhibitor concentrations were chosen according
to their ability to inhibit osteoclast resorption in overnight pit
forming assays or their effects in electrophysiology experiments
(Bennett et al., 2001; Albert et al., 2005) or as reported in the liter-
ature (Murrills and Dempster, 1990; Lakkakorpi et al., 1996; Chen
et al., 2002). In each experiment three independent dentine slices
were used and experiments were repeated at least twice with cells
from different rabbits. The total number of osteoclasts that were
analyzed per inhibitor treatment varied between 350 and 670.
IMMUNODETECTION
Resorbing osteoclasts were identiﬁed by immunostaining
with anti-αvβ3 antibodies (clone 23C6) and/or staining with
ﬂuorophore-conjugated phalloidin. After ﬁxation the cells were
incubated for 30 min in 5% newborn bovine serum in PBS
containing 0.02% sodium azide (wash) and then processed for
immunodetection. Primary antibodies were diluted in wash and
the cells were incubated for 30 min at RT. Bound antibodies were
detected with AlexaFluor 488-conjugated goat anti-mouse sec-
ondary antibodies. For triple-labeling experiments cells stained
with anti-αvβ3 antibodies were incubated with AlexaFluor 647-
conjugated phalloidin for 30min at RT.
MICROSCOPY
TRITC-labeled dextran and antibody/actin distribution wasmon-
itored with a Leica TCS-NT confocal laser-scanning microscope
(CSLM; Heidelberg, Germany), using standard ﬁlter settings and
sequential scanning to avoid overlap of emission from the ﬂuo-
rophores. The thickness of the optical section was set to 1.013 μm
for the xy sections and to 1.008 μm for the zx sections. In some
images the xy sectionswere added togetherwith the extended focus
option of the Leica TCS-NT software to allow the visualization of
the area just above the bone surface to the bottom of the pit. The
xy sections were used to count the number of endocytosis-positive
osteoclasts. Osteoclasts were considered endocytosis-positive if
they showed robust red vesicular staining in the resorption area;
zx sections were used to conﬁrm endocytosis if xy sections were
ambiguous.
STATISTICAL ANALYSIS
All experimentswere repeated at least twice and in each experiment
the number of αvβ3 antibody-positive, multinucleated cells was
determined and examined for TRITC-labeled dextran 3,000 endo-
cytosis. In experimentswith inhibitors, at least 350osteoclastswere
observed to determine the number of endocytosis-positive cells.
Results obtained for each experiment were expressed as percentage
of endocytosis-active osteoclasts over total number of osteoclasts
(±SD) and compared to vehicle-treated controls. In some exper-
iments the number of endocytosis-active osteoclasts was set to
zero to visualize the effect of the treatment on restoring control
conditions, i.e., inhibiting the effect of calcitonin. Results from two
to ﬁve independent experiments were pooled before plotting. We
determined the normal distribution of the data by ﬁtting a Gaus-
sian function on the entire dataset. Differences were analyzed by
Student’s t-test and considered signiﬁcant if p < 0.05.
RESULTS
CALCITONIN AND cAMP ELEVATION INTERFERE WITH ENDOCYTOSIS
IN ACTIVELY RESORBING OSTEOCLASTS
In accordance with previously published results (Lucht, 1973;
Baron et al., 1990), pre-incubation of rabbit osteoclasts plated
on dentine slices with 20 nM calcitonin for 30 min markedly
reduces the number of osteoclasts showing endocytosis com-
pared to control samples (Figures 1A,B). In other cell sys-
tems cAMP and subsequent activation of PKA has been shown
to interfere with endocytosis and transcytosis (Bradbury et al.,
1992; Hansen and Casanova, 1994; Cotlin et al., 1999). We
show here that in osteoclasts elevating the intracellular cAMP
concentration by adding a membrane permeable cAMP ana-
log (Kopperud et al., 2003) and the phosphodiesterase inhibitor
IBMX has only a limited effect on osteoclast endocytosis from
the rufﬂed border (Figures 1A,B). In our experiments, we
used both 8-bromo-cAMP,which also activates exchange-protein-
directly activated-by-cAMP (Epac), and monobutyl cAMP (6-
MB-cAMP), which is speciﬁc for PKA (Cheng et al., 2008).
Using these two cAMP analogs we obtained identical results
(11% ± 11.2 reduction in the number of osteoclast with endo-
cytosis). However, when adenylate cyclase was directly activated
by forskolin, the number of osteoclasts with endocytosis was
reduced below the level obtained with these cAMP analogs
alone or together with the phophodiesterase inhibitor IBMX
(67% ± 14; 89% ± 11.2; 80% ± 4, respectively; Figure 1B).
These results indicate that cAMP signaling effectors other than
PKA may play a role in regulating endocytosis in osteoclasts.
We thus tested the effect of inhibiting PKA directly with either
H89 or Rp-cAMPS. These inhibitors have different modes of
action; H89 blocks the ATP binding site of PKA whereas Rp-
cAMPS is an inhibitory analog of cAMP (Lochner and Mool-
man, 2006). After overnight culture, osteoclasts on dentine
were pre-incubated for 5 min with H89 or for 10 min with
Rp-cAMPS, before addition of calcitonin for 30 min and sub-
sequent addition of TRITC-labeled dextran 3,000 for 5 min.
Treatment with 4 μM H89 for 35 min on its own statistically
signiﬁcantly lowered the number of endocytosis-active osteo-
clasts by 64% to 36% ± 14.8, and the addition of calcitonin
had no further effect. In contrast, we observed only a mild
inhibition with Rp-cAMPS (16.9% ± 18.3) and a response
to calcitonin similar to vehicle-treated cells (54.3% ± 18.1;
Figure 1B). These ﬁndings clearly indicate that as observed in
other cell systems, H89 inhibits a number of different path-
ways that are distinct from PKA (Lochner and Moolman, 2006;
Palacios et al., 2007).
PLC SIGNALING MEDIATES THE INHIBITORY EFFECT OF
CALCITONIN ON ENDOCYTIC TRAFFICKING
To investigatewhether the calcitonin-mediated inhibitionof endo-
cytic trafﬁcking requires the PLC pathway, after overnight culture
osteoclasts on dentine slices were incubated for 5 min with 1 μM
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FIGURE 1 | Incubation of osteoclasts with 20 nM calcitonin for 30 min
reduces endocytosis in osteoclasts.This effect is only partially mimicked
by addition of forskolin to directly activate adenylate cyclase, or by raising
intracellular cAMP with 6-MB-cAMP (cAMP) alone or together with the
phosphodiesterase inhibitor IBMX. Inhibiting signaling pathways
downstream of cAMP does not reverse the calcitonin effect. Exposure of
osteoclasts to 4 μM of the PKA inhibitor H89 for 30 min lowers the number
of endocytosis-active osteoclasts to a level comparable to calcitonin
addition. Incubation of the cells with H89 for 5 min before the addition of
calcitonin does not reverse the calcitonin-mediated inhibition of
endocytosis. The inhibitory analog of cAMP, Rp-cAMPS, has only limited
effects on endocytosis on its own and does not reverse the response to
calcitonin. (A) Lateral view of rabbit osteoclasts plated on dentine after
incubation with vehicle, calcitonin or 6-MB-cAMP for 30 min. Red,
TRITC-dextran; arrow, endocytosedTRITC-dextran; open arrow, rufﬂed
border area without endocytosis; green, anti-αvβ3 antibodies. Scale bar:
10 μm. (B) Chart showing the inhibitory effect of the different drugs when
compared to endocytosis in vehicle-treated cells. Results are average of
three independent experiments. Error bars represent standard deviation,
signiﬁcant reductions in dextran endocytosis compared to control are
marked: *p < 0.05, **p < 0.005, individual p-values are shown above
the bars.
of the PLC inhibitor U-73122 before addition of calcitonin.
Treatment with the inhibitor restores endocytic trafﬁcking to 77%
of control cells (Figures 2A,B). PLC signaling gives rise to two sec-
ond messengers, DAG and IP3. IP3 activates calcium efﬂux from
intracellular stores whereas DAG, in conjunction with calcium,
activates PKC and several other molecules, as recently reported
(Sossin and Farah, 2009).
FIGURE 2 | PLC but not PKC signaling conveys the inhibitory effect of
calcitonin on endocytosis. Osteoclasts plated on dentine for 16 h were
pre-incubated for 5 min with either the PLC inhibitor U-73122 (1 μM) or the
PKC inhibitor bisindolylmaleimide (1 μM) or the PKC activator PMA (1 μM)
before the addition of calcitonin for 30 min. TRITC-dextran 3,000 was then
added for 5 min before ﬁxation. Cells were immunodecorated with
antibodies directed against αvβ3 integrin. (A) Representative lateral view of
treated cells. Red, TRITC-dextran; arrow, endocytosedTRITC-dextran; open
arrow, rufﬂed border area without endocytosis; green, anti-αvβ3 antibodies.
Scale bar: 10 μm.Treatment with the PLC inhibitor restores endocytic
trafﬁcking whereas neither the PKC inhibitor nor the PKC activator PMA has
an effect. (B)The number of osteoclasts displaying endocytosed dextran
was counted and expressed as percentage of total. Columns show mean
percentage of osteoclasts with dextran endocytosis compared to calcitonin
treatment alone (set to 0). Results are average of three independent
experiments. Error bars show standard deviation and signiﬁcant increases
in endocytosis-active osteoclasts are marked: *p < 0.05. Treatment with
the PLC inhibitor restores endocytic trafﬁcking to 77% whereas neither
inhibiting nor activating PKC has an effect on the reduction in
endocytosis-active osteoclasts after calcitonin treatment.
To investigate the role of PKC in osteoclast endocytosis, we pre-
treated the cells with the PKC inhibitors bisindolylmaleimide or
chelerythrine for 5 min before the addition of calcitonin. Treat-
ment with both inhibitors resulted in reduction of endocytosis
to a level below that observed with calcitonin alone (43% ± 6.6
versus 54.5% ± 7.9, respectively; Figure 2B). In contrast to the
results obtained with H89, pre-treatment with the PKC inhibitors
had no signiﬁcant effect on endocytic trafﬁcking (92% osteoclasts
showed endocytosis compared to control; data not shown). To
test whether PKC activation independent of PLC activation can
interfere with calcitonin signaling to the endocytic machinery in
osteoclasts, we treated the osteoclasts for 5 min with Phorbol-12-
Myristate-13-acetate (PMA), which directly activates PKC. Pre-
treatment with PMA did not reverse calcitonin-induced reduction
in the number of endocytosis-active osteoclasts (50.95% ± 12.09;
Figure 2B).
POLYUNSATURATED FATTY ACIDS BUT NOT DAG ARE IMPORTANT
FOR ENDOCYTIC TRAFFICKING
To further elucidate the pathway by which PLC activation inhibits
endocytic trafﬁcking in osteoclasts we used the DAG kinase
inhibitor R59949 and the DAG lipase inhibitor RHC 80267 to
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FIGURE 3 | PUFA are important for endocytic trafficking. Rabbit
osteoclasts plated on dentine were incubated for 16 h before a 15 min
pre-incubation with either the DAG kinase inhibitor R55949 or the DAG
lipase inhibitor RHC 80267 (both 10 μM) before the addition of 20 nM
calcitonin for 30 min. TRITC-dextran 3,000 was then added for 5 min before
ﬁxation. The number of osteoclasts presenting endocytosed dextran was
counted after immunodecoration with antibodies directed against the αvβ3
integrin and expressed as percentage of total. Columns show mean
percentage of osteoclasts with dextran endocytosis and standard
deviation. Results are average of two independent experiments. Signiﬁcant
reductions in dextran endocytosis are marked: *p < 0.05, **p < 0.005,
individual p-values are shown above the bars.
increase the intracellular DAG levels. DAG kinases are the main
enzymes responsible for termination of the DAG signal. In recent
years, it has become clear that DAG can activate targets other than
PKC, someof which are important for vesicle fusion. Adirect activ-
ity onion channels has also been reported (Sossin andFarah,2009).
Interestingly, increasing the concentration of DAG with the DAG
kinase inhibitor did not reverse the calcitonin effect (66.3%± 10.3
versus 54.5% ± 7.9, respectively; Figure 3). However, inhibiting
the production of polyunsaturated fatty acids (PUFA) by block-
ing DAG lipase had a statistically signiﬁcant negative effect on
endocytic trafﬁcking (39% ± 8.06; Figure 3) and did not reverse
the calcitonin effect, highlighting the importance of fatty acids
in this process (Stock and Coderre, 1984; Brown et al., 2003;
Spilsberg et al., 2007).
CALCIUM DYNAMICS ARE NECESSARY FOR ENDOCYTIC TRAFFICKING
AND ARE AFFECTED BY CALCITONIN TREATMENT
PLC activation increases intracellular calcium via the generation
of IP3 and calcium release from internal stores. To study the
inﬂuence of calciumon endocytic trafﬁcking after calcitonin treat-
ment, we used several independent approaches. First, we clamped
the intracellular calcium concentration via BAPTA-AM, a cell
permeable calcium chelator. Treatment of cells with calcitonin
in the presence of 50 μM BAPTA-AM augmented the inhibitory
effect of calcitonin (59.7% ± 1.8 compared to 46.8% ± 7.9 with
calcitonin alone), indicating that intracellular calcium plays an
important role in the regulation of endocytosis (Figure 4A). Treat-
ment of osteoclasts with BAPTA-AM alone for 30 min had only
a modest inhibitory effect on the number of endocytosis-positive
osteoclasts (22% ± 9.2; data not shown).
To check involvement of calcium release from intracellular
stores we used the ionophore ionomycin and thapsigargin, which
interferes with reﬁlling of intracellular stores by inhibiting sar-
coplasmic/endoplasmic reticulumCa2+-dependentATPase pump
(SERCA). Interestingly, both ionomycin and thapsigargin restored
endocytic activity in osteoclasts after calcitonin treatment and
had their largest effect when added soon after addition of cal-
citonin. Incubation of calcitonin together with thapsigargin or
ionomycin restored endocytic trafﬁcking to 23 (±13.05) and 43%
(±5.75), respectively. However, addition of ionomycin or thapsi-
gargin 1.5min after calcitonin restored trafﬁcking to 47 (±7.8) and
72.7% (±1.9) of control, respectively (Figure 4A). In agreement
with previously published results, the actin cytoskeleton was not
affected by treatment with the intracellular calcium modulators
(BAPTA-AM, thapsigargin or ionomycin) for 30 min (Lakkako-
rpi et al., 1996; Figure 4B). In contrast to the reversal of the
inhibitory effect of calcitonin on intracellular trafﬁcking, treat-
ment with the intracellular calcium modulators did not overturn
the effect that calcitonin has on the actin cytoskeleton (Figure 4C).
Taken together with the results obtained using the PKC inhibitors
these ﬁndings strongly suggest that calcitonin affects endo-
cytic trafﬁcking by reducing intracellular calcium levels in
osteoclasts.
DISCUSSION
A precise control of vesicular trafﬁcking is crucial for endocytosis
and exocytosis in osteoclasts, and as such, for bone homeosta-
sis. Factors regulating membrane trafﬁcking in these cells are
therefore paramount for controlling bone dynamics and may
represent novel avenues for therapeutic intervention in bone
pathologies. The recent discovery that osteoclasts play a signiﬁcant
role in providing bone-forming signals has led to renewed inter-
est in calcitonin as a treatment for osteoporosis and osteoarthritis
(Henriksen et al., 2010). Here we used calcitonin as a tool to inves-
tigate the regulation of endocytic trafﬁcking inmature osteoclasts.
Calcitonin elicitsmultiple effects on osteoclasts, which include ces-
sation of intracellular trafﬁcking to and from the rufﬂed border
(Lucht, 1973; Baron et al., 1990) via a complex signaling network
(Inzerillo et al., 2002).
Independent evidence demonstrates the effect of calcitonin on
the osteoclast actin cytoskeleton, which leads to a decrease in cell
motility. These effects aremediated by high intracellular cAMP. So
far, no experimental evidence links cAMP signaling events to the
cessation of membrane trafﬁcking after calcitonin treatment. In
other cell types, cAMP has been shown to stimulate exocytosis and
to reduce clathrin-mediated and ﬂuid phase endocytosis (Brad-
bury et al., 1992; Gekle et al., 1995; Bouley et al., 2011) as well as to
enhance transcytosis (Hansen and Casanova, 1994). We were thus
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FIGURE 4 | Calcium fluctuations are essential for endocytic trafficking
from the ruffled border. Rabbit osteoclasts plated on dentine for 16 h
were incubated with 20 nM calcitonin and indicated concentrations of
calcium modulators for 30 min before the addition of TRITC-dextran 3,000
for 5 min and ﬁxation. 1 μM ionomycin or 100 nM thapsigargin were either
added together with calcitonin (1) or were added 1.5 min after addition of
calcitonin (2). (A) Chart showing the effects of different inhibitors. The
number of osteoclasts presenting endocytosed dextran was counted after
immunodecoration with antibodies directed against the αvβ3 integrin and
expressed as percentage of total. Columns show mean percentage of
osteoclasts with dextran endocytosis in comparison to calcitonin treatment
alone (set to 0). Error bars represent SD, signiﬁcant increases in dextran
endocytosis over calcitonin treatment are marked: *p < 0.05, individual
p-values are shown above the bars. (B) Morphology of the
actin-cytoskeleton after exposure to calcium modulators. Rabbit
osteoclasts plated on dentine were exposed for 30 min to 50 μM
BAPTA-AM; 1 μM ionomycin; 100 nM thapsigargin before addition of
TRITC-dextran 3,000 for 5 min, ﬁxation and immunodecoration. Red,
TRITC-dextran; green, anti-αvβ3 antibodies; blue, actin cytoskeleton. The
resorption area enclosed by the actin ring is indicated with arrows. (C)
Osteoclasts on dentine were incubated for 30 min with 20 nM calcitonin
together with 50 μM BAPTA-AM; 1 μM ionomycin or 100 nM thapsigargin.
Red, TRITC-dextran; green, anti-αvβ3 antibodies, blue, actin-cytoskeleton.
Disorganized actin ﬁlaments in the cells treated with calcitonin are
highlighted with open arrows. Scale bars: 10 μm.
interested to determine the effect of elevating intracellular cAMP
levels on TRITC-labeled dextran 3,000 endocytosis. We increased
intracellular cAMP by usingmembrane permeable cAMP analogs,
forskolin or via PKA activation. PKA is a well-known target
of cAMP but there are several other molecules, most notably
the Epacs, that are stimulated by a rise in intracellular cAMP
concentration (Cheng et al., 2008). Our results show that forskolin
has amore pronounced effect on the number of endocytosis-active
osteoclasts than the cell-membranepermeable cAMPanalogs, sug-
gesting that the calcitonin effect on endocytosis is partially due to
a combination of Epac- and PKA-derived downstream signals.
However, the fact that the cAMP analog 8-bromo-cAMP, which
activates both PKA and Epac, did not produce different results to
the PKA-speciﬁc 6-MB-cAMP indicates that there might be other
cAMP-sensitive signaling pathways triggered by calcitonin that are
mediating its inhibitory effects on endocytosis. This hypothesis
is supported by the results obtained with the established PKA
inhibitorsH89 andRp-cAMPS,which failed to restore endocytosis
after calcitonin treatment. Instead, we found that H89 profoundly
reduced the number of endocytosis-active osteoclasts both with
and without calcitonin treatment. Even though a negative effect of
PKA inhibition on vesicular trafﬁcking has been demonstrated
in other cell systems (Butterworth et al., 2005; Bejarano et al.,
2006; Wojtal et al., 2008), there is also evidence that H89 inhibits
several other kinases at concentrations similar to those blocking
PKA (Lochner and Moolman, 2006). This is also the most likely
scenario in our experiments, since the inhibitory cAMP analog
(Rp-cAMPS) did not show the same effects asH89. Taken together,
our results demonstrate that cAMP-dependent signaling is not
essential in the inhibition elicited by calcitonin on the endocytic
machinery, and that the effect observed with H89 in osteoclasts is
due to the inhibition of another kinase (Lee and Linstedt, 2000;
Lochner and Moolman, 2006).
The other classical signaling pathway activated by calcitonin
is the PLC- PKC-calcium pathway (Su et al., 1992). To estab-
lish whether this pathway is involved in the calcitonin-dependent
modulation of the endocytic machinery, we used a PLC inhibitor,
a PKC inhibitor as well as a PKC activator. PKC activation has
been shown to induce changes in tyrosine phosphorylation of
cell adhesion kinases, which leads to disruption of the periph-
eral actin ring in osteoclasts and is involved in cell retraction
after calcitonin treatment (Zhang et al., 2002; Shyu et al., 2007).
Interestingly, the PLC inhibitor reversed the calcitonin effect and
restored endocytic trafﬁcking to almost control levels. Surpris-
ingly, however this effect was not mediated by PKC. In recent
years, it has become clear that there are other factors besides PKC
that are stimulated by second messengers generated by PLC acti-
vation, such as DAG. DAG on its own has a number of membrane
trafﬁc relevant effects, including regulation of SNARE complex
formation and direct ion channel stimulation (Sossin and Farah,
2009). Additionally, products of DAG inactivation by DAG lipases
(PUFA) and kinases (phosphatidic acid) have been shown tomod-
ulate intracellular trafﬁcking (Darios et al., 2007; Donaldson,2009;
Davletov and Montecucco, 2010; Malhotra and Campelo, 2011).
We thus investigated the effect of increasing DAG by using the spe-
ciﬁc DAG lipase inhibitor RHC 80267 and DAG kinase inhibitor
R59949. ElevatedDAG levels had no effect on calcitonin-mediated
inhibition of TRITC-dextran 3,000 endocytosis, but blocking the
generation of PUFA with RHC 80267 decreased the number of
endocytosis-active osteoclasts. These results clearly demonstrate
an important role of PUFA in osteoclasts activity, in addition
to their role in osteoclast differentiation (Kruger et al., 2010;
Yuan et al., 2010).
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PLC activation increases intracellular calcium, an effect also
observed upon calcitonin treatment (Malgaroli et al., 1989; Xia
and Ferrier, 1996). When the concentration of intracellular cal-
cium was increased using thapsigargin, a SERCA inhibitor, or
the ionophore ionomycin, endocytic trafﬁcking was restored in
calcitonin-treated cells. This recovery was almost complete when
the calcium increase followed a brief incubation with calcitonin.
These results are similar to what has been previously observed by
Malgaroli et al. (1989) where a brief pre-incubation with calci-
tonin augmented the rise in intracellular calcium elicited by high
extracellular calcium levels. Xia and Ferrier (1996) showed that
calcitonin stimulated localized calcium changes, which consisted
of repetitive short-lasting spikes and single pulses in different
areas of the cells. It will be thus important in the future to
measure intracellular calcium changes in response to inhibitor
and calcitonin treatment in situ by loading resorbing osteo-
clasts on bone with ﬂuorescent calcium indicators such as Fura-2
AM or Fluo-4 AM. These experiments will also further our
studies on the effects of calcitonin on transient receptor poten-
tial (TRP) channels (Albert et al., 2010). TRP channels have
recently received much interest because they have been found
to regulate osteoclast differentiation and calcium sensing (Ben-
nett et al., 2001; van der Eerden et al., 2005; Guilak et al., 2010).
TRP channels have a wide range of functions, one of which
is store-operated calcium entry after depletion of intracellular
stores. It is thus possible that the initial rise in intracellular
calcium concentration after treatment of the cells with thapsi-
gargin or ionomycin is sustained by inﬂux of calcium through
store-operated channels. Since sustained increases in intracellu-
lar calcium trigger osteoclast apoptosis (Mentaverri et al., 2003),
this effect should be short lived in order for cells to sur-
vive. As calcitonin does not cause osteoclast apoptosis, it is
unlikely that a sustained intracellular calcium elevation is tak-
ing place after calcitonin treatment. This hypothesis is supported
by our ﬁndings on the morphology of the actin cytoskeleton
after treatment with calcium modulators. Previous reports have
shown a profound effect of increased intracellular calcium on
osteoclast cytoskeleton. In contrast, we did not observe actin
redistribution after incubating the cells for 30 min with calcium
modulators. These results are in agreement to those reported
by Lakkakorpi et al. (1996) demonstrating a very short effect
of ionomycin on the actin cytoskeleton in osteoclasts plated on
bone slices.
Taken together, our results clearly suggest an important role
for calcium in osteoclast endocytosis. Recently, thapsigargin has
been shown to inhibit autophagic ﬂow by blocking the fusion of
autophagosomeswith lysosmes (Ganley et al., 2011). As autophagy
genes, such as Atg5, play an important role in osteoclast ruf-
ﬂed border formation we cannot rule out a compensatory effect
on endocytic trafﬁcking induced by thapsigargin. However Atg5
which is also involved in thapsigargin-induced autophagy, does
not play a role in endosome uptake and trafﬁcking from the ruf-
ﬂed border (DeSelm et al., 2011). It is thus more likely that it
is the thapsigargin-induced calcium release that is relieving the
calcitonin-induced block in endocytic trafﬁcking. In neurons and
chromafﬁn cells, a rise in intracellular calcium triggers exocy-
tosis, however, other trafﬁcking steps, such as endocytosis also
depend on intracellular calcium (Hosoi et al., 2009; Rosa et al.,
2011). These ﬁndings are in line with our observations that clamp-
ing intracellular calcium with the cell-permeable calcium chelator
BAPTA-AM reduced the number of endocytosis-active osteoclasts
and did not reverse the effect of calcitonin.
In summary, we have identiﬁed an important regulatory func-
tion of calcium signaling in endocytosis from the rufﬂed border
in osteoclasts. Increasing intracellular calcium may modulate the
endocytic machinery through calcineurin, calmodulin, and/or
calmodulin-dependent protein kinase II regulation of compo-
nents of membrane trafﬁc machinery, such as dynamin (Smillie
and Cousin, 2005), EEA1, and syntaxin (Risinger and Bennett,
1999) in addition to facilitating bilayer fusion (Peters and Mayer,
1998). Synaptotagmins are calcium sensors involved inmembrane
fusion and synaptotagmin VII has been shown to be essential for
the regulation of exocytosis towards the rufﬂed border in osteo-
clasts (Zhao et al., 2008). In agreement with the recently described
role of synaptotagmin I in clathrin-mediated endocytosis at nerve
terminals (Yamashita, 2012), our ﬁndings suggest the exciting pos-
sibility that an increase in intracellular calcium couples exo- and
endocytosis in osteoclasts via synaptotagmin VII.
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